Actively Recruiting
[18F] F-GLN by PET/CT in Breast Cancer
Led by Abramson Cancer Center at Penn Medicine · Updated on 2026-01-22
40
Participants Needed
1
Research Sites
399 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Patients with known or suspected primary or metastatic breast cancer with one lesion that is 1.0 cm in diameter or greater may be eligible for this study. Patients may participate in this study if they are at least 18 years of age. Up to 40 evaluable subjects will participate in a single imaging cohort. Patients will be stratified for analysis by breast cancer subtype with prioritization to recruit at least 10 estrogen-receptor-expressing (ER+) and 10 triple-negative breast cancers (TNBC). Participants may be treatment naïve or have received up to 3 weeks of treatment at the time of the \[18F\]F-Gln PET/CT scan. This is an observational study; \[18F\]F-GLN PET/CT will not be used to direct treatment decisions. While patients and referring physicians will not be blinded to the \[18F\]F-GLN PET/CT results, treatment decisions are made by the treating physicians based upon clinical criteria. \[18F\]F-GLN PET/CT imaging sessions will include an injection of \[18F\]F-GLN. Metabolism data will be collected. Pilot data will be collected to evaluate image quality and collect preliminary information on the uptake of \[18F\]F-GLN in breast cancer. Uptake measures will be compared to tumor markers of glutamine metabolism, when tissue is available. The safety of \[18F\]F-GLN will also be evaluated in all subjects.
CONDITIONS
Official Title
[18F] F-GLN by PET/CT in Breast Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants will be 18 years of age or older
- Known or suspected primary or metastatic breast cancer
- At least one lesion 1.0 cm or larger visible on standard imaging (CT, MRI, mammogram, ultrasound, or FDG-PET/CT)
- Willing to provide informed consent and participate according to institutional and federal guidelines
You will not qualify if you...
- Females who are pregnant or breastfeeding at screening; urine pregnancy test required for women of child-bearing potential
- Unable to tolerate imaging procedures as judged by investigator or treating physician
- Any medical condition or disorder that may compromise safety or successful study participation as assessed by physician
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
Actively Recruiting
Research Team
E
Erin Schubert
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here